Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
Sujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, Michael Trang, Justin C Bader, Catharine C Bulik, Brian D VanScoy, Christopher M Rubino, Michael D Huband, Lawrence Friedrich, Judith N Steenbergen, Paul G Ambrose
Author Information
Sujata M Bhavnani: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA. ORCID
Jeffrey P Hammel: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Elizabeth A Lakota: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Michael Trang: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA. ORCID
Justin C Bader: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Catharine C Bulik: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.
Brian D VanScoy: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA. ORCID
Christopher M Rubino: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA. ORCID
Michael D Huband: JMI Laboratories, North Liberty, Iowa, USA. ORCID
Lawrence Friedrich: Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Judith N Steenbergen: Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Paul G Ambrose: Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA. ORCID
Omadacycline, a novel aminomethylcycline with activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae, is approved in the United States to treat patients with community-acquired bacterial pneumonia (CABP). Using nonclinical pharmacokinetic-pharmacodynamic (PK-PD) targets for efficacy and surveillance data for omadacycline against S. pneumoniae and H. influenzae, and a population pharmacokinetic model, PK-PD target attainment analyses were undertaken using total-drug epithelial lining fluid (ELF) and free-drug plasma exposures to evaluate omadacycline 100 mg intravenously (i.v.) every 12 h or 200 mg i.v. every 24 h (q24h) on day 1, followed by 100 mg i.v. q24h on day 2 and 300 mg orally q24h on days 3 to 5 for patients with CABP. Percent probabilities of PK-PD target attainment on days 1 and 2 by MIC were assessed using the following four approaches for selecting PK-PD targets: (i) median, (ii) second highest, (iii) highest, and (iv) randomly assigned total-drug ELF and free-drug plasma ratio of the area under the concentration-time curve to the MIC (AUC/MIC ratio) targets associated with a 1-log CFU reduction from baseline. Percent probabilities of PK-PD target attainment based on total-drug ELF AUC/MIC ratio targets on days 1 and 2 were ≥91.1% for S. pneumoniae for all approaches but the highest target and ≥99.2% for H. influenzae for all approaches at MICs (0.12 and 1 μg/mL for S. pneumoniae and H. influenzae, respectively). Lower percent probabilities of PK-PD target attainment based on free-drug plasma AUC/MIC ratio targets were observed for randomly assigned and the highest free-drug plasma targets for S. pneumoniae and for all targets for H. influenzae. These data provided support for approved omadacycline dosing regimens to treat patients with CABP and decisions for the interpretive criteria for the susceptibility testing of omadacycline against these pathogens.
